Jul 23, 2021 6:30am EDT Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer’s Disease
Jul 01, 2021 6:30am EDT Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer’s Disease
Jun 17, 2021 4:30pm EDT Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter’s Over-allotment Option for Gross Proceeds of $14.4 Million
Mar 12, 2021 6:41am EST Alzamend Neuro®, Inc. announces an agreement to sell $10,000,000 of its securities to Digital Power Lending LLC, a subsidiary of Ault Global Holdings, Inc.
Dec 29, 2020 5:44pm EST Alzamend Neuro®, Inc. Announces Confidential Submission of Draft Registration Statement Relating to the Proposed Initial Public Offering of Its Common Stock
Nov 16, 2020 9:00am EST Alzamend Neuro®, Inc. Registration is Closing to Join the Shareholder and Investor Conference Call and Webcast Set for Tomorrow, November 17, 2020 to Provide Update and Plans for 2021
Nov 03, 2020 9:45am EST Alzamend Neuro®, Inc. Announces Shareholder and Investor Conference Call and Webcast to Provide Update and Plans for 2021
Oct 27, 2020 6:56am EDT New Immunomodulatory Therapeutic Vaccine that Targets Oligomeric Amyloid-β Could be Step Towards Halting Alzheimer’s Disease Progression
